Evaluating radiotherapy for abdominal and pelvic cancers
Radiotherapy Treatments for Neoplasms in the Abdominal-pelvic Region
This study is testing how well radiotherapy works for people with cancers in the abdominal and pelvic areas to see if it can improve their treatment outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 7700 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | European Institute of Oncology Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT06335238 on ClinicalTrials.gov |
What this trial studies
This study evaluates the clinical and dosimetric aspects, tolerance, and effectiveness of radiotherapy treatments for patients with primary or secondary neoplasms localized in the abdominal-pelvic region. Approximately 60% of patients with such neoplasms receive radiotherapy as part of their treatment, which may be combined with other systemic or surgical interventions. The study aims to collect data from these patients to identify correlations between treatment parameters and outcomes, ultimately guiding more effective treatment strategies. The data collected will contribute to scientific dissemination and help establish operational protocols for future treatments.
Who should consider this trial
Good fit: Ideal candidates include patients undergoing radiotherapy for various primary or secondary tumors in the abdominal-pelvic region.
Not a fit: Patients receiving radiotherapy for cancers located outside the abdominal-pelvic region will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with abdominal and pelvic cancers.
How similar studies have performed: Other studies have shown success in evaluating radiotherapy treatments for similar conditions, indicating that this approach is supported by existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients treated with radiotherapy for curative, palliative, neo-adjuvant, and adjuvant purposes in the abdominal-pelvic region for: Primary tumors of the gastrointestinal tract, Primary tumors of the male and female reproductive systems, Primary tumors of the urinary system, Primary tumors of the cardio-circulatory system, Primary tumors of the lymphatic system, Primary tumors of the nervous system, Skin tumors, Secondary abdominal-pelvic localizations of various origins, Primary or secondary bone or soft tissue lesions of the lumbosacral spine and pelvis. 2. Signed informed consent Exclusion Criteria: 1. Radiotherapy in districts other than the abdominal-pelvic region
Where this trial is running
Milan
- European Institute of Oncology — Milan, Italy (Recruiting)
Study contacts
- Principal investigator: Barbara Alicja Jereczek — European Institute of Oncology
- Study coordinator: Barbara Alicja Jereczek
- Email: barbara.jereczek@ieo.it
- Phone: +39 02 57489326
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.